123-I ioflupane (Datscan®) presynaptic nigrostriatal imaging in patients with movement disordersAbstracts
123-I Ioflupane (Datscan®) presynaptic imaging has been shown to have a significant utility in the assessment of patients with movement disorders 123-I Ioflupane SPECT is able to distinguish between Parkinson’s disease (PD) and other forms of parkinsonism without degeneration of the nigrostriatal pathway, including a common movement disorder such as essential tremor, and to assess disease progression in PD and other neurodegenerative disorders involving the substantia nigra.
123-I Ioflupane; dopamine transporter imaging; movement disorders; Parkinson’s disease
